"Osme" means smell in Greek, and Osmetech is intent on finding ways to sniff out what's wrong with people. Founded in 1993, the company has several molecular diagnostics products on the market. Its eSensor system can detect RNA and DNA targets, such as genes that indicate sensitivity to certain drugs, as well as for detecting cystic fibrosis carriers. Though headquartered in the UK, the company's principal operations are in the US. Its diagnostic systems, tubes, and microarrays are used by hospitals, laboratories, and physician practices through its US sales force and a network of international distributors.

Genzyme Biosurgery may turn you into the Six Million Dollar Man, but it can't do anything about your Six Million Dollar Medical Bill. The Genzyme Corp. division develops biotech products for orthopedic procedures. Top sellers include knee osteoarthritis treatment Synvisc and Carticel, which repairs damaged knee cartilage. Genzyme Biosurgery's biosurgical specialties unit makes Seprafilm, which prevents tissue adhesions after surgery. Other products include those to assist in adhesion prevention and hernia repair (Sepramesh) and severe burn treatment (Epicel).

Silence Therapeutics wants to put the kibosh on disease-causing genes. The company, formerly known as SR Pharma, is working in the field of RNA interference (RNAi), a cutting-edge approach to treating disease that involves interfering with, or silencing, targeted genes associated with disease. Its AtuPLEX drug delivery system is designed to work specifically with RNA molecules. Silence Therapeutics acquired fellow RNAi research company Intradigm in 2010, greatly expanding its RNAi program capabilities, which it hopes will make it a more attractive partner to bigger pharmaceutical companies looking to develop products based on that science.

EntreMed, Inc. was founded in 1991 and is headquartered in Rockville, Maryland. EntreMed, Inc. (EntreMed) is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells and the blood vessels that nourish them. The Company focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. The Company has four compounds in clinical development with a pipeline of orally-active, multi-mechanism drugs for the treatment of cancer including; MKC-1, a cell cycle inhibitor, Panzem (2-methoxyestradiol or 2ME2), and ENMD-1198, an antimitotic agent. EntreMed also has active investigational new drug (IND) for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076, and Panzem for rheumatoid arthritis.

Simcere Pharmaceutical Group was founded in 1995 and is headquartered in Nanjing, the People's Republic of China. Simcere Pharmaceutical Group is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. The Company has introduced a generic anti-stroke medication under the brand name Bicun, a 5-FU sustained release implant under the brand name Sinofuan and an anti-cancer medication under the brand name Endu. It manufactures and sells 45 principal pharmaceutical products and is the distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand names. On May 5, 2008, it acquired 70% interest in Wuhu Zhong Ren Pharmaceutical Co., Ltd. (Wuhu Simcere Zhong Ren). On January 6, 2009, Simcere Pharmaceutical Group acquired the remaining 10% of interest of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd. (Shandong Simcere).

MaxCyte will put your blood cells to work. Its cell loading technology uses blood cells instead of viral vectors to transport gene therapies to target sites, increasing their safety and efficacy. The company partners with drug makers to help them develop more effective therapies in a shorter amount of time. Partners include AlphaVax, Sangamo BioSciences, and United Therapeutics. MaxCyte is also working on its own therapies, including potential treatments for chronic lymphocytic leukemia, lymphoma, and breast and ovarian cancer. CEO Douglas Doerfler and other backers control the company after EntreMed spun it off.

Carma Laboratories, Inc. company was founded by Alfred Woelbing, who developed the formula for Carmex in 1937 as a treatment for his own cold sores. Carma Laboratories wants to make it easier for you to smile and sit. The family-owned-and-operated company is most famous for its retro yellow-lidded vials of Carmex lip balm. The company also makes Am-Ren, a zinc-oxide based diaper rash ointment, and LANEX hemorrhoid ointment to soothe cracked and painful tissues elsewhere. Once sold mostly in the Midwest and the ski areas of the Rockies, Carmex soothes lips in all 50 states, Canada, Australia, and Europe.

Icagen, Inc. company was founded in 1992 and is based in Durham, North Carolina. Icagen, Inc. (Icagen) is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The Company’s programs include ICA-105665 for epilepsy and neuropathic pain, for which the Company is conducting a Phase I multiple ascending dose study in healthy volunteers and epilepsy patients and Senicapoc, previously referred to as ICA-17043, for asthma, for which the Company is conducting two Phase II proof-of-concept clinical trials.

Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York. Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company's commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Aflibercept for the treatment of oncology; VEGF Trap-Eye in wet AMD in patients for eye diseases; and ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. The company's products under clinical trials include REGN88, an antibody to the Interleukin-6 receptor (IL-6R) that is being evaluated in patients with rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4 that is being developed for oncology; and REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases. The company has strategic collaboration agreements with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye.

Axcan Pharma Inc. company develops and sells drugs mainly to treat gastrointestinal ailments. Its Urso line treats chronic liver disease, while two of its products (Canasa and Salofalk) offer relief for inflammatory bowel diseases. Axcan's Ultrase and Viokase are digestive aids for patients with exocrine pancreatic insufficiency, a condition associated with cystic fibrosis. The firm also owns the global rights to Photofrin, a photodynamic drug developed by QLT with applications for esophageal, gastric, and lung cancers. Other products include ulcer and diarrhea treatments, as well as chewable multivitamins. Axcan was acquired by TPG Capital for $1.3 billion in early 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.